The 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC) took place on the 8th-12th of November 2022 in Boston, MA, and virtually. Leading experts discussed practice-changing trial updates and the latest news in immuno-oncology!
View all videos

SITC 2022

Society for Immunotherapy of Cancer 37th Annual Meeting
08–12 November 2022 | Boston, MA

SITC 2022

Society for Immunotherapy of Cancer 37th Annual Meeting
08–12 November 2022 | Boston, MA
The 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC) took place on the 8th-12th of November 2022 in Boston, MA, and virtually. Leading experts discussed practice-changing trial updates and the latest news in immuno-oncology!
View all videos

Latest videos from SITC 2022!

View all videos
2:02
Fibrosis enhances glycocalyx modification and immune suppression in tumors
Valerie Weaver • 1 Nov 2022
1:52
Targeting and rehabilitating immunosuppressive myeloid cells
Valerie Weaver • 1 Nov 2022
3:27
How can racial disparities affect patient care in oncology?
Carmen Guerra • 7 Nov 2022
1:59
The role of tissue tension and myeloid cells in modulating tumor immunity
Kevin Tharp • 1 Nov 2022

Lung Cancer at SITC 2022!

View all
1:20
Pixatimod and nivolumab in metastatic melanoma, NSCLC and MSS CRC
Diwakar Davar • 7 Nov 2022
2:53
Delta-radiomics predicting response and overall-survival in advanced NSCLC treated with durvalumab
Anant Madabhushi • 26 Oct 2022
5:24
Clinical applications of pentose phosphate pathway activation in immunotherapy
Geoffrey Markowitz • 8 Nov 2022
10:24
Enhancing PD-1 blockade by inhibiting PKM2 activity in the pentose phosphate pathway
Geoffrey Markowitz • 8 Nov 2022

Skin Cancer at SITC 2022!

View all
2:01
Developing novel T-cell therapeutics for patients with melanoma who do not respond to ICI’s
Cristina Puig Saus • 31 Oct 2022
2:16
Landscape analysis of neoepitope-specific T-cell responses depending on clinical benefit from ICIs
Cristina Puig Saus • 31 Oct 2022
2:58
Results of a Phase II trial of vidutolimod and nivolumab in melanoma
Diwakar Davar • 7 Nov 2022
4:17
Microbiome modification with fecal transplant before IO to reduce primary resistance in melanoma
Saman Maleki • 2 Nov 2022

Antibodies at SITC 2022!

View all
4:17
Microbiome modification with fecal transplant before IO to reduce primary resistance in melanoma
Saman Maleki • 2 Nov 2022
5:15
Combination myeloid cell and T-cell targeting as an effective anti-tumor strategy
Judith Varner • 3 Nov 2022
4:27
Key updates in immunotherapies for melanoma
Diwakar Davar • 7 Nov 2022
1:20
Pixatimod and nivolumab in metastatic melanoma, NSCLC and MSS CRC
Diwakar Davar • 7 Nov 2022

Checkpoint Inhibitors at SITC 2022!

View all
4:27
Key updates in immunotherapies for melanoma
Diwakar Davar • 7 Nov 2022
1:07
The multidisciplinary nature of treating myocarditis
Han Zhu • 27 Oct 2022
1:20
Pixatimod and nivolumab in metastatic melanoma, NSCLC and MSS CRC
Diwakar Davar • 7 Nov 2022
2:00
Remaining challenges in reducing or preventing cardiotoxicity in patients receiving immunotherapy
Han Zhu • 27 Oct 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals